Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biophytis Sa ADR (NQ: BPTS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biophytis Sa ADR

< Previous 1 2 3 Next >
Biophytis: Convening of Another Combined General Meeting at a Later Date
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on... 
From Biophytis
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 12, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on... 
From Biophytis
Via AccessWire
Exposures COVID-19
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2022 / Biophytis SA ((NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused... 
From Biophytis
Via AccessWire
Exposures COVID-19
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
- Success of Nasdaq IPO in February 2021 - €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 - Strong growth... 
From Biophytis
Via AccessWire
Topics Initial Public Offering
Exposures COVID-19 Securities Market
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
- Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 - COVID-19 (COVA): 237... 
From Biophytis
Via AccessWire
Exposures COVID-19 Product Safety
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized... 
From Biophytis
Via AccessWire
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 16,2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on... 
From Biophytis
Via AccessWire
Exposures COVID-19
Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program
- ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit - Sarconeos... 
From Biophytis
Via AccessWire
Exposures COVID-19
Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / December 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), a clinical-stage biotechnology company focused on the development of... 
From Biophytis
Via AccessWire
Topics Bonds
Exposures Debt Markets
Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3
- Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development - A Type B/End-of-Phase 2 meeting is planned... 
From Biophytis
Via AccessWire
Exposures COVID-19 Product Safety
Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company... 
From Biophytis
Via AccessWire
Topics Bonds Regulatory Compliance
Exposures COVID-19 Debt Markets Legal
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 15, 2021 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company... 
From Biophytis
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused... 
From Biophytis
Via AccessWire
Topics Bonds Derivatives Regulatory Compliance
Exposures COVID-19 Debt Markets Derivatives
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.